Abstract

Existing data suggest that NF-kappaB signaling is a key regulator of cancer-induced skeletal muscle wasting. However, identification of the components of this signaling pathway and of the NF-κB transcription factors that regulate wasting is far from complete. In muscles of C26 tumor bearing mice, overexpression of dominant negative (d.n.) IKKβ blocked muscle wasting by 69% and the IκBα-super repressor blocked wasting by 41%. In contrast, overexpression of d.n. IKKα or d.n. NIK did not block C26-induced wasting. Surprisingly, overexpression of d.n. p65 or d.n. c-Rel did not significantly affect muscle wasting. Genome-wide mRNA expression arrays showed upregulation of many genes previously implicated in muscle atrophy. To test if these upregulated genes were direct targets of NF-κB transcription factors, we compared genome-wide p65 binding to DNA in control and cachectic muscle using ChIP-sequencing. Bioinformatic analysis of ChIP-sequencing data from control and C26 muscles showed very little p65 binding to genes in cachexia and little to suggest that upregulated p65 binding influences the gene expression associated with muscle based cachexia. The p65 ChIP-seq data are consistent with our finding of no significant change in protein binding to an NF-κB oligonucleotide in a gel shift assay, no activation of a NF-κB-dependent reporter, and no effect of d.n.p65 overexpression in muscles of tumor bearing mice. Taken together, these data support the idea that although inhibition of IκBα, and particularly IKKβ, blocks cancer-induced wasting, the alternative NF-κB signaling pathway is not required. In addition, the downstream NF-κB transcription factors, p65 and c-Rel do not appear to regulate the transcriptional changes induced by the C26 tumor. These data are consistent with the growing body of literature showing that there are NF-κB-independent substrates of IKKβ and IκBα that regulate physiological processes.

Highlights

  • Cachexia is a metabolic condition associated with many chronic diseases and it is characterized by the severe wasting of skeletal muscle and adipose tissue which cannot be reversed by increasing caloric intake [1]

  • Our findings are consistent with those of Cai et al [5] showing a role for IkBa in cancer wasting, and for the first time we show that IKKb is required for the development of cancer cachexia, but inhibitor of kappaB kinase alpha (IKKa) and NF-kB inducing kinase (NIK) are not

  • We constructed the IkBaSREGFP fusion plasmid that we have described in detail [16]

Read more

Summary

Introduction

Cachexia is a metabolic condition associated with many chronic diseases and it is characterized by the severe wasting of skeletal muscle and adipose tissue which cannot be reversed by increasing caloric intake [1]. Cancer patients with cachexia have a lower quality of life due to compromised immune function, insulin resistance, weakness, and fatigue [2]. Patients with even mild cachexia cannot tolerate chemotherapy treatment, which further exacerbates their illness [3]. Cachexia is estimated to contribute to the deaths of approximately 30% of cancer patients [4]. Since the more severe consequences of cachexia seem to reside with skeletal muscle loss [1], developing a better understanding of the cellular signaling mechanisms and gene regulation in muscle could yield novel therapeutic strategies for treatment of this condition

Objectives
Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.